Latest Pharma Insights
Rarity Bioscience Sees Way Forward For superRCA Liquid Biopsy Platform, Despite Challenges
Entering the liquid biopsy market with a new technology remains challenging. Rarity Bioscience CEO Linus Bosaeus, is confident his company’s superRCA could help unlock the true potential of precision medicine as pharma looks more to minimal residual disease as an oncology endpoint.
Medtech Insight - November 21, 2025
Entering the liquid biopsy market with a new technology remains challenging. Rarity Bioscience CEO Linus Bosaeus, is confident his company’s superRCA could help unlock the true potential of precision medicine as pharma looks more to minimal residual disease as an oncology endpoint.
Medtech Insight - November 21, 2025
Five Things To Know From Moderna’s Analyst Day
Still betting on its vaccines portfolio, Moderna is also hoping to deliver on its ambitions in oncology with a Phase III candidate partnered with Merck, while cutting pipeline programs and seeking manufacturing efficiencies.
Scrip - November 21, 2025
Still betting on its vaccines portfolio, Moderna is also hoping to deliver on its ambitions in oncology with a Phase III candidate partnered with Merck, while cutting pipeline programs and seeking manufacturing efficiencies.
Scrip - November 21, 2025
Ovid CEO Meg Alexander Takes The Helm In Time To Harvest Growing Blooms
Meg Alexander is taking the place of founder Jeremy Levin, who is transitioning to executive chair, as Ovid prepares to move lead drug OV329 into a Phase IIa epilepsy study and generate initial data for its first-in-class KCC2 direct activators.
Scrip - November 21, 2025
Meg Alexander is taking the place of founder Jeremy Levin, who is transitioning to executive chair, as Ovid prepares to move lead drug OV329 into a Phase IIa epilepsy study and generate initial data for its first-in-class KCC2 direct activators.
Scrip - November 21, 2025
CIR Poised To Reject Read-Across For Lash Conditioning Agents In Setback For Non-Animal Tests
In what would be a blow to efforts to encourage use of read-across and other non-animal methods in cosmetic safety assessments, a proposal from a cosmetic ingredient working group suggests that animal test data is necessary to assess the safety of two prostaglandin analogues.
HBW Insight - November 21, 2025
In what would be a blow to efforts to encourage use of read-across and other non-animal methods in cosmetic safety assessments, a proposal from a cosmetic ingredient working group suggests that animal test data is necessary to assess the safety of two prostaglandin analogues.
HBW Insight - November 21, 2025
Contineum’s PIPE-307 Fails Phase II MS Trial, Focus Shifts To IPF Candidate
Disappointing topline data in the Phase II VISTA multiple sclerosis trial for PIPE-307 shifts the spotlight to Contineum’s idiopathic pulmonary fibrosis candidate PIPE-791.
Scrip - November 21, 2025
Disappointing topline data in the Phase II VISTA multiple sclerosis trial for PIPE-307 shifts the spotlight to Contineum’s idiopathic pulmonary fibrosis candidate PIPE-791.
Scrip - November 21, 2025
Jefferies 25: Bayer R&D Boss Pours Cold Water On Asundexian Hopes
Stroke data on the Factor XIa inhibitor are due before the end of the year but pharma research chief Christian Rommel is not getting too excited.
Scrip - November 21, 2025
Stroke data on the Factor XIa inhibitor are due before the end of the year but pharma research chief Christian Rommel is not getting too excited.
Scrip - November 21, 2025
GSK and AnaptysBio Lock Horns Over Jemperli Deal
The future of a 2014 licensing deal for the potential blockbuster is in question after partners GSK and AnaptysBio initiated legal action against each other.
Scrip - November 21, 2025
The future of a 2014 licensing deal for the potential blockbuster is in question after partners GSK and AnaptysBio initiated legal action against each other.
Scrip - November 21, 2025
Jefferies 25: Merck’s Cidara Buyout Could Help Meet Needs Of Increasingly Vaccine-Hesitant US
Cidara’s long-acting antibody candidate could help protect millions of immunocompromised patients against flu – and could work around growing vaccine hesitancy in the US.
Scrip - November 21, 2025
Cidara’s long-acting antibody candidate could help protect millions of immunocompromised patients against flu – and could work around growing vaccine hesitancy in the US.
Scrip - November 21, 2025
Amphastar Expects Mysterious Inhaler Candidate To Be The ‘Most Meaningful’ Revenue Driver In 2026
Amphastar sees two highly likely launches in 2026, with one of them significantly contributing to next year's revenues. However, both generics are yet to be approved by the US FDA.
Generics Bulletin - November 21, 2025
Amphastar sees two highly likely launches in 2026, with one of them significantly contributing to next year's revenues. However, both generics are yet to be approved by the US FDA.
Generics Bulletin - November 21, 2025
Alvotech Positioned As Sole Simponi Biosimilar For ‘Months’ With EU Approval
Approval of Gobivaz across the 30-country EEA introduces long-awaited competition to Simponi, though the partners have yet to confirm a commercial launch date.
Generics Bulletin - November 21, 2025
Approval of Gobivaz across the 30-country EEA introduces long-awaited competition to Simponi, though the partners have yet to confirm a commercial launch date.
Generics Bulletin - November 21, 2025
Formycon Must Be ‘Self-Critical’ As Biosimilar Competition Intensifies
As Formycon’s fourth-quarter sales and a key pembrolizumab biosimilar deal become critical to guidance, management hinted that deeper organizational changes may be required.
Generics Bulletin - November 21, 2025
As Formycon’s fourth-quarter sales and a key pembrolizumab biosimilar deal become critical to guidance, management hinted that deeper organizational changes may be required.
Generics Bulletin - November 21, 2025
Notified Bodies Have Availability Now - But The Situation Won’t Last
Medtech companies should not look at the current period as a regulatory hiatus, but as an opportunity to avoid a crisis two to three years down the line.
Medtech Insight - November 21, 2025
Medtech companies should not look at the current period as a regulatory hiatus, but as an opportunity to avoid a crisis two to three years down the line.
Medtech Insight - November 21, 2025
Opella Takes Top Prize At OTC Marketing Awards 2025
Winners across 12 categories were announced at the OTC Marketing Awards 2025 on 20 November, with Opella crowned OTC Company of the Year.
HBW Insight - November 21, 2025
Winners across 12 categories were announced at the OTC Marketing Awards 2025 on 20 November, with Opella crowned OTC Company of the Year.
HBW Insight - November 21, 2025
Hanmi Secures North America Beachhead Via Aptose Acquisition
Hanmi is acquiring the Toronto-based biotech, Aptose, following positive early data of its lead asset tuspetinib in AML. The deal also gives Hanmi a strategic foothold in North America and marks another oncology-focused acquisition by a Korean pharma firm.
Scrip - November 21, 2025
Hanmi is acquiring the Toronto-based biotech, Aptose, following positive early data of its lead asset tuspetinib in AML. The deal also gives Hanmi a strategic foothold in North America and marks another oncology-focused acquisition by a Korean pharma firm.
Scrip - November 21, 2025
Prebiotic Ingredient Firm Comet Forecasts Trail Of GLP-1 Popularity Driving Gut Health Concern
Canadian firm states in 2026 forecast that its research, including consumer surveys and sales data, shows a majority of consumers, 65%, are not only familiar with the benefits of prebiotics but also interested in the ingredients, 55%.
HBW Insight - November 21, 2025
Canadian firm states in 2026 forecast that its research, including consumer surveys and sales data, shows a majority of consumers, 65%, are not only familiar with the benefits of prebiotics but also interested in the ingredients, 55%.
HBW Insight - November 21, 2025
Abbott’s $21Bn Buyout Of Exact Sciences Paves Way To Fast-Growing Cancer Screening Market
Abbott will acquire Exact Sciences for $21bn, which marks the largest such deal ever in the diagnostics space. The deal will allow Abbott to enter the fast-growing $60bn US cancer screening market.
Medtech Insight - November 21, 2025
Abbott will acquire Exact Sciences for $21bn, which marks the largest such deal ever in the diagnostics space. The deal will allow Abbott to enter the fast-growing $60bn US cancer screening market.
Medtech Insight - November 21, 2025
Five Things To Know From Moderna’s Analyst Day
Still betting on its vaccines portfolio, Moderna is also hoping to deliver on its ambitions in oncology with a Phase III candidate partnered with Merck, while cutting pipeline programs and seeking manufacturing efficiencies.
Scrip - November 21, 2025
Still betting on its vaccines portfolio, Moderna is also hoping to deliver on its ambitions in oncology with a Phase III candidate partnered with Merck, while cutting pipeline programs and seeking manufacturing efficiencies.
Scrip - November 21, 2025
Ovid CEO Meg Alexander Takes The Helm In Time To Harvest Growing Blooms
Meg Alexander is taking the place of founder Jeremy Levin, who is transitioning to executive chair, as Ovid prepares to move lead drug OV329 into a Phase IIa epilepsy study and generate initial data for its first-in-class KCC2 direct activators.
Scrip - November 21, 2025
Meg Alexander is taking the place of founder Jeremy Levin, who is transitioning to executive chair, as Ovid prepares to move lead drug OV329 into a Phase IIa epilepsy study and generate initial data for its first-in-class KCC2 direct activators.
Scrip - November 21, 2025
Contineum’s PIPE-307 Fails Phase II MS Trial, Focus Shifts To IPF Candidate
Disappointing topline data in the Phase II VISTA multiple sclerosis trial for PIPE-307 shifts the spotlight to Contineum’s idiopathic pulmonary fibrosis candidate PIPE-791.
Scrip - November 21, 2025
Disappointing topline data in the Phase II VISTA multiple sclerosis trial for PIPE-307 shifts the spotlight to Contineum’s idiopathic pulmonary fibrosis candidate PIPE-791.
Scrip - November 21, 2025
Jefferies 25: Bayer R&D Boss Pours Cold Water On Asundexian Hopes
Stroke data on the Factor XIa inhibitor are due before the end of the year but pharma research chief Christian Rommel is not getting too excited.
Scrip - November 21, 2025
Stroke data on the Factor XIa inhibitor are due before the end of the year but pharma research chief Christian Rommel is not getting too excited.
Scrip - November 21, 2025
GSK and AnaptysBio Lock Horns Over Jemperli Deal
The future of a 2014 licensing deal for the potential blockbuster is in question after partners GSK and AnaptysBio initiated legal action against each other.
Scrip - November 21, 2025
The future of a 2014 licensing deal for the potential blockbuster is in question after partners GSK and AnaptysBio initiated legal action against each other.
Scrip - November 21, 2025
Jefferies 25: Merck’s Cidara Buyout Could Help Meet Needs Of Increasingly Vaccine-Hesitant US
Cidara’s long-acting antibody candidate could help protect millions of immunocompromised patients against flu – and could work around growing vaccine hesitancy in the US.
Scrip - November 21, 2025
Cidara’s long-acting antibody candidate could help protect millions of immunocompromised patients against flu – and could work around growing vaccine hesitancy in the US.
Scrip - November 21, 2025
Hanmi Secures North America Beachhead Via Aptose Acquisition
Hanmi is acquiring the Toronto-based biotech, Aptose, following positive early data of its lead asset tuspetinib in AML. The deal also gives Hanmi a strategic foothold in North America and marks another oncology-focused acquisition by a Korean pharma firm.
Scrip - November 21, 2025
Hanmi is acquiring the Toronto-based biotech, Aptose, following positive early data of its lead asset tuspetinib in AML. The deal also gives Hanmi a strategic foothold in North America and marks another oncology-focused acquisition by a Korean pharma firm.
Scrip - November 21, 2025
Rarity Bioscience Sees Way Forward For superRCA Liquid Biopsy Platform, Despite Challenges
Entering the liquid biopsy market with a new technology remains challenging. Rarity Bioscience CEO Linus Bosaeus, is confident his company’s superRCA could help unlock the true potential of precision medicine as pharma looks more to minimal residual disease as an oncology endpoint.
Medtech Insight - November 21, 2025
Entering the liquid biopsy market with a new technology remains challenging. Rarity Bioscience CEO Linus Bosaeus, is confident his company’s superRCA could help unlock the true potential of precision medicine as pharma looks more to minimal residual disease as an oncology endpoint.
Medtech Insight - November 21, 2025
Notified Bodies Have Availability Now - But The Situation Won’t Last
Medtech companies should not look at the current period as a regulatory hiatus, but as an opportunity to avoid a crisis two to three years down the line.
Medtech Insight - November 21, 2025
Medtech companies should not look at the current period as a regulatory hiatus, but as an opportunity to avoid a crisis two to three years down the line.
Medtech Insight - November 21, 2025
Abbott’s $21Bn Buyout Of Exact Sciences Paves Way To Fast-Growing Cancer Screening Market
Abbott will acquire Exact Sciences for $21bn, which marks the largest such deal ever in the diagnostics space. The deal will allow Abbott to enter the fast-growing $60bn US cancer screening market.
Medtech Insight - November 21, 2025
Abbott will acquire Exact Sciences for $21bn, which marks the largest such deal ever in the diagnostics space. The deal will allow Abbott to enter the fast-growing $60bn US cancer screening market.
Medtech Insight - November 21, 2025
CIR Poised To Reject Read-Across For Lash Conditioning Agents In Setback For Non-Animal Tests
In what would be a blow to efforts to encourage use of read-across and other non-animal methods in cosmetic safety assessments, a proposal from a cosmetic ingredient working group suggests that animal test data is necessary to assess the safety of two prostaglandin analogues.
HBW Insight - November 21, 2025
In what would be a blow to efforts to encourage use of read-across and other non-animal methods in cosmetic safety assessments, a proposal from a cosmetic ingredient working group suggests that animal test data is necessary to assess the safety of two prostaglandin analogues.
HBW Insight - November 21, 2025
Opella Takes Top Prize At OTC Marketing Awards 2025
Winners across 12 categories were announced at the OTC Marketing Awards 2025 on 20 November, with Opella crowned OTC Company of the Year.
HBW Insight - November 21, 2025
Winners across 12 categories were announced at the OTC Marketing Awards 2025 on 20 November, with Opella crowned OTC Company of the Year.
HBW Insight - November 21, 2025
Prebiotic Ingredient Firm Comet Forecasts Trail Of GLP-1 Popularity Driving Gut Health Concern
Canadian firm states in 2026 forecast that its research, including consumer surveys and sales data, shows a majority of consumers, 65%, are not only familiar with the benefits of prebiotics but also interested in the ingredients, 55%.
HBW Insight - November 21, 2025
Canadian firm states in 2026 forecast that its research, including consumer surveys and sales data, shows a majority of consumers, 65%, are not only familiar with the benefits of prebiotics but also interested in the ingredients, 55%.
HBW Insight - November 21, 2025
Amphastar Expects Mysterious Inhaler Candidate To Be The ‘Most Meaningful’ Revenue Driver In 2026
Amphastar sees two highly likely launches in 2026, with one of them significantly contributing to next year's revenues. However, both generics are yet to be approved by the US FDA.
Generics Bulletin - November 21, 2025
Amphastar sees two highly likely launches in 2026, with one of them significantly contributing to next year's revenues. However, both generics are yet to be approved by the US FDA.
Generics Bulletin - November 21, 2025
Alvotech Positioned As Sole Simponi Biosimilar For ‘Months’ With EU Approval
Approval of Gobivaz across the 30-country EEA introduces long-awaited competition to Simponi, though the partners have yet to confirm a commercial launch date.
Generics Bulletin - November 21, 2025
Approval of Gobivaz across the 30-country EEA introduces long-awaited competition to Simponi, though the partners have yet to confirm a commercial launch date.
Generics Bulletin - November 21, 2025
Formycon Must Be ‘Self-Critical’ As Biosimilar Competition Intensifies
As Formycon’s fourth-quarter sales and a key pembrolizumab biosimilar deal become critical to guidance, management hinted that deeper organizational changes may be required.
Generics Bulletin - November 21, 2025
As Formycon’s fourth-quarter sales and a key pembrolizumab biosimilar deal become critical to guidance, management hinted that deeper organizational changes may be required.
Generics Bulletin - November 21, 2025
ADC Innovation: Record Funding Fuels Tubulis’s Clinical Push Into 2026
“Tubulis is not a single-asset company… It’s an innovation powerhouse,” said CEO Dominik Schumacher in an interview with In Vivo. He outlined the company’s clinical progress, funding momentum and how Tubulis will navigate the competitive biotech market in 2026.
In Vivo - November 19, 2025
“Tubulis is not a single-asset company… It’s an innovation powerhouse,” said CEO Dominik Schumacher in an interview with In Vivo. He outlined the company’s clinical progress, funding momentum and how Tubulis will navigate the competitive biotech market in 2026.
In Vivo - November 19, 2025
Deals In Depth: October 2025
Eleven $1bn+ alliances were penned in October, and four exceeded $2bn. In the top alliance by deal value, Innovent Biologics entered into a potential $11.4bn collaboration with Takeda to co-develop and commercialize next-generation immuno-oncology and antibody-drug conjugate cancer therapies.
In Vivo - November 19, 2025
Eleven $1bn+ alliances were penned in October, and four exceeded $2bn. In the top alliance by deal value, Innovent Biologics entered into a potential $11.4bn collaboration with Takeda to co-develop and commercialize next-generation immuno-oncology and antibody-drug conjugate cancer therapies.
In Vivo - November 19, 2025
Clinical Trial Roundup: Oncology Dominates, Cardiovascular Surges, Infectious Disease Declines
In 2024, trial initiations shifted following the post-pandemic decline in COVID-19 studies. Cardiovascular trials showed the greatest growth by therapeutic area but trailed the previous year’s initiation levels.
In Vivo - November 19, 2025
In 2024, trial initiations shifted following the post-pandemic decline in COVID-19 studies. Cardiovascular trials showed the greatest growth by therapeutic area but trailed the previous year’s initiation levels.
In Vivo - November 19, 2025
Podcast: Data-Driven Insights Reveal The Growth Engines Powering 2026 Life Sciences
In this special In Vivo podcast episode, executive editor Lucie Ellis-Taitt is joined by an expert panel of Citeline journalists – Ashley Yeo, David Wild, Jessica Merrill and data journalist Edwin Elmhirst – to explore the trends set to reshape the biopharma and medtech sectors as we head into 2026.
In Vivo - November 19, 2025
In this special In Vivo podcast episode, executive editor Lucie Ellis-Taitt is joined by an expert panel of Citeline journalists – Ashley Yeo, David Wild, Jessica Merrill and data journalist Edwin Elmhirst – to explore the trends set to reshape the biopharma and medtech sectors as we head into 2026.
In Vivo - November 19, 2025